Introduction
Iron participates in a wide variety of key metabolic processes of living organisms, including oxygen and electron transport and DNA synthesis. Transferrin receptor-1 (TFR-1), a homodimeric membrane glycoprotein clustered as CD71, plays a major role in the uptake of transferrin-bound iron 1, 2 . Beside the dominant TFR-1-mediated endocytosis, cellular iron uptake may also be obtained through TFR-1-independent pathways 3 . Human TFR-2 is a newly identified member of the TFR family, serendipitously cloned while attempting to isolate genes encoding transcription factors 4 . Based on the predicted amino acid sequence, TFR-2 is a type II trans-membrane protein with a 66% similarity to TFR-1 in the extracellular domain 4 .
Major differences between TFR-2 and TFR-1 concern mRNA tissue distribution and regulation of expression. Northern and RT-PCR analyses showed that the message for TFR-2 is predominantly detected in the liver and -among a panel of cell lines -in HepG2
(hepatocarcinoma) and K562 (erythroleukemia) 4 . In addition, high levels of TFR-2 mRNA are found in normal early erythroid precursors and in myeloid leukemic blasts 5 .
TFR-2 is hypothesized to bind iron-loaded TF and to transport iron into the cytosol, as inferred from a model of CHO cells transfected with TFR-2 and constitutively lacking TFR-1 4, 6 . However, the function of TFR-2 is not equivalent to that of TFR-1: murine TFR-2 does not replace TFR-1 functions, and TFR-1-deficient mice do not survive beyond embryonic day 12.5, because of neurologic abnormalities and severe anemia 7 . Moreover, mice with only one functional TFR-1 allele have mild tissue iron depletion 7 , whereas inactivation of TFR-2 in humans results in hemochromatosis (HH) type 3, a genetic form of iron overload [8] [9] [10] .
Regulation of TFR-2 expression is clearly distinct from that of TFR-1. The most striking differences are the lack of iron responsive elements in the TFR-2 mRNA and the absence of only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013 . bloodjournal.hematologylibrary.org From 5 the iron-dependent post-transcriptional regulation that characterizes other key genes of iron metabolism 6 . At variance with TFR-1, TFR-2 is apparently insensitive to tissue iron status and it is not down modulated in a murine model of HH 11, 12 .
This work reports on the production of a panel of monoclonal antibodies (mAbs) and a murine polyclonal antiserum specific for TFR-2. These reagents were used to analyze the tissue distribution of TFR-2 and to study its behavior following exposure to the physiological ligand.
only.
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Materials and Methods

Preparation of a construct enclosing the full length cDNA of human TFR-2
A TFR-2 cDNA was prepared by RT-PCR starting from the poly-A RNA of the HepG2 cell line. Touch down PCR was carried out using expand TM long template PCR system (Boehringer-Mannheim, Mannheim, Germany). After reverse transcription (42 °C, 60 min, terminated by heating for 2 min at 94 °C), PCR was performed for 8 cycles (denaturation: 1 min, 94 °C; annealing: 1 min, 64 °C, with a lowering increment of 2 °C / cycle; elongation: 5 min, 68 °C). Termocycling was continued for up to 38 cycles (denaturation 1 min at 94 °C, annealing 1 min at 56 °C and elongation 7 min at 68 °C). All RT-PCR reactions were performed using an automated thermal cycler (Perkin Elmer, Boston, MA) with primers selected according to the published sequence.
An aliquot (1 µl) of the reaction product was ligated to a pcDNA3.1 expression vector by the TA-Cloning system and transformation was carried out on E. coli TOP10 cells (all from Invitrogen, Carlsbad, CA). Positive transformants were analyzed for presence and correct orientation of TFR-2 cDNA both by PCR and by digestion with the NcoI restriction enzyme (New England Biolabs, Beverly, MA) and partial sequencing. The results confirmed that the TFR-2 was identical to the reported one (GeneBank Accession XM 005011). The selected transformants, indicated as TFR-2/pcDNA3.1, were grown in LB medium and purified by the Quantum Prep plasmid midiprep kit (Biorad, Hercules, CA).
Transfection and selection
20 µg of the TFR-2/pcDNA3.1 were linearized by treatment with 20 IU/mg of the ScaI restriction enzyme (New England Biolabs) and used to stably transfect NIH-3T3 cells by electroporation (250 V/0.4 cm and 960 µF). After a 2-week incubation in a medium containing 1 mg/ml G418 (Sigma-Aldrich, Milano, Italy), neomycin resistant colonies were only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From isolated and the presence of the TFR-2 cDNA checked by RT-PCR. As a final confirmation of the identity of the cDNA, a restriction enzyme map and an internal fragment PCR amplification were obtained. A fragment corresponding to exons 3-4 of the TFR-2 was amplified using the following primers: forward 5' GGGCCTTCCTACTGGG 3', reverse 5' CCACACGTGGTCCAGGTTCTGGGGGGA 3' 4 . Positive colonies were isolated and recloned by serial dilution to ensure clonality. NIH-3T3 cells were similarly transfected with an empty pcDNA3.1 vector and selected using G418 13 .
Cells and specimens
The HepG2 and K562 cell lines were selected in view of their high levels of TFR-2 RNA expression. Murine L-fibroblasts transfected with the human TFR-1 (L-CD71 + ) were obtained as described 14 . The solid tumor and hematological cell lines used in the study are listed in table 1.
The study included specimens derived from human organs obtained from the Pathology Department of the University of Torino. Surgical biopsies of normal tissues were obtained following ablative surgery of various malignancies from patients free from chemo-and radiotherapies. Iron-poor (APO) and iron-saturated (HOLO) TF were purchased from Sigma. Anti-CD71 mAbs used included CB26 and MyBe, locally produced and purified 14 and H68.4 purchased from Zymed (San Francisco, CA). The anti HLA-Class I mAb NL02 15 was used as control .
Peptides and reagents
Antibody production
A panel of specific murine mAbs was produced using NIH-3T3/TFR-2/4B1 as immunizer.
Briefly, 2x10 5 The primary cultures fulfilling the binding requisites of the selection grid were cloned three times by limiting dilution and subsequently grown as tumor ascites in pristane-primed mice.
The mAbs were purified using an HPLC technique after purification on Protein A 18 .
A U.K.), as described 19 . Immunoblotting was performed using as probe either the mAbs or the polyclonal antiserum, later highlighted by means of rabbit Ig conjugated to horse radish peroxidase (Sigma). The reaction was revealed using a CDP-STAR chemiluminescent reagent (NEN-Life Science Products, Boston, MA) and the membranes subjected to autoradiography.
Indirect immunofluorescence
The surface expression of TFR-2 was determined by indirect immunofluorescence ( 
Tissue distribution
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From
The distribution of TFR-2 as recognized by the different mAbs was examined on different tissues using formalin-fixed paraffin-embedded tissues of surgical specimens. Endogenous peroxidase and endogenous biotin were inhibited as described elsewhere 20 . Heat-induced antigen retrieval was performed by a pre-treatment in a microwave oven (three times for 3 min at 750 W) of the sections incubated in 1mM EDTA buffer (pH 8.0) or in 10 mM citrate buffer (pH 6.0) 21 . After incubation with the specific mAb, the reaction was revealed using the universal LSAB 2 streptavidin kit (Dako, Glostrup, Denmark).
Analysis of TF-TFR-2 interactions
The adherent cell lines HepG2 and U251 were grown on glass coverslips and treated at 37 °C with APO-TF and HOLO-TF, used at concentrations varying from 10 to 50 µg/ml. analyzed with a C-VIEW-12-BUND camera fitted to an Olympus 1X70 microscope (Olympus, Milano, Italy), with the images collected using the ANALYSIS software. K562 cells were stained in suspension for TFR-2 and TFR-1 expressions after identical treatments and evaluated by cytofluorography using a FACSort equipment, as above.
Results
Generation of murine fibroblasts stably expressing the human TFR-2 transcript
The murine NIH-3T3 fibroblastoid cells, electroporated in the presence of a pcDNA3.1 vector enclosing the full length human TFR-2 construct and selected for growing in G418-conditioned medium, were used as immunizers and as target cells for the successive experiments. The cells surviving G418 were further selected on the basis of the RT-PCR results for TFR-2 presence. The clone 4B1 fulfilled all the requisites and was further subcloned by limiting dilution, constantly kept under metabolic selection and referred to as NIH-3T3/TFR-2/4B1. Transfection with the empty plasmid resulted in the production of G418-resistant clones, not expressing TFR-2 and hereinafter referred to as mock transfected NIH-3T3.
Production of monoclonal and polyclonal antibodies
The NIH-3T3/TFR-2/4B1 cells were used to immunize Balb/c mice directly into the spleen. 
Specificity of the mAbs and the polyclonal antiserum produced
The specifity of the mAbs and antiserum selected was confirmed by reacting with mouse fibroblasts transfected with the human TFR-1. The absence of any binding consented also to rule out any cross-reactivity with human TFR-1. Same experiments were performed on HL-60 cell line (constitutively TFR-1 + ), obtaining the same reactivity pattern ( figure 3, panel a) .
Western blot analysis of the target structure
Western blot analyses were used to identify the structure recognized by the mAbs and the polyclonal antiserum and to confirm the specificity of the reaction. G/14E8 mAb recognized For 
Distribution of the human TFR-2 in normal tissues
The tissue distribution of TFR-2 was initially evaluated by assaying the reactivity of the panel of mAbs with frozen or formalin-fixed sections from non-pathological liver, selected as reported to display high levels of TFR-2 mRNA. The reactivity of the anti-TFR-2 mAbs was comparatively evaluated per se and versus the expression of TFR-1, as recognized by specific mAbs. The TFR-2 and TFR-1 proteins were localized in serial tissue sections by using an immunoperoxidase method. The results indicate that 3 out of 9 mAbs, namely G/5F8, G/14C2 and G/1C11, display a clear reactivity with the frozen samples, which is maintained when the tissue is formalin-fixed (figure 4 a-c). These mAbs were used for a detailed analysis of TFR-2 distribution in normal liver. The results indicate that TFR-2 is i) present at high density in hepatocytes, that ii) the reactivity is prevalently cytosolic (figure 5d-e), and that iii) The expression of TFR-2 was seen also among a subpopulation of lamina propria lymphocytes, where TFR-1 is also present at high density (figure 5b and 5e, arrows).
Samples from normal adult pancreas, lungs, ovaries, uterus, breast, prostate and adrenals were not stained by the TFR-2 mAbs.
Functional behavior in response to TF
The in vivo functions of TFR-2 remain elusive in spite of an important sequence similarity with the canonical TFR-1. Previous reports have shown that it may mediate iron uptake, only.
Discussion
The biological functions and tissue distribution of TFR-2 remain undefined. Experimental evidence indicates that TFR-2 may mediate iron uptake: however, its affinity for iron-loaded TF is remarkably lower than that of TFR-1 22, 6 , suggesting that iron uptake is not the principal or the only function of TFR-2. Inactivation of TFR-2 causes a form of HH with features similar to HFE-related HH [8] [9] [10] , hinting to a regulatory role for TFR-2 in iron metabolism. Most available data concern TFR-2 mRNA expression, while studies on the protein were insofar limited by the lack of specific reagents. To investigate its structure, tissue distribution and function(s), we developed 9 murine mAbs and a murine polyclonal antiserum against TFR-2, exploiting a highly sensitive immunization protocol and adopting screening strategies derived from the experience of the CD Workshop on Differentiation Antigens.
Results provide i) a preliminary structural blueprint of human TFR-2 based on the identification of discrete domains of the molecule, ii) an analysis of TFR-2 tissue distribution, and iii) information about the receptorial behavior following exposure to the TF ligand. The finding that only 3 of the 9 selected mAbs clearly react with the liver sections indicates the existence of 2 major epitopes of the TFR-2 molecule, as seen from for the murine immune system. These epitopes are presently under analysis by walking on the molecule using peptides spanning the TFR-2 sequence and by testing the signaling potential of the specific mAbs and the polyclonal antiserum.
Western blot analyses confirm that the mAbs are specific for TFR-2, reacting with a dominant band of 90 kD in HepG2 along with a minor band of 105 kD in K562 cell lines.
Other minor components are stained by the different mAbs and confirmed by the antiserum.
The presence of tissue-specific isoforms or of cell-specific glycosilations is a matter of only.
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The analysis of TFR-2 distribution in different tissues indicates that the protein is prevalently expressed by cells which play a prominent role in the regulation of iron homeostasis. Indeed, high levels of expression were found in hepatocytes, a major iron storage site, and in the enterocytes of the crypts and villi, localized in the portions of the GI tract involved in iron absorption. The distribution of TFR-2 was strikingly different from that of TFR-1 in normal tissues not taking part to the regulation of iron metabolism and in continuous cell lines (data not shown), but was similar in liver and small intestine, suggesting a role of TFR-2 in the regulation of iron homeostasis. According to a current hypothesis, the sensing of body iron needs is carried out by the crypt cells and likely involves uptake of iron from circulating TF 23 -25 . In agreement with this view, an impaired iron uptake from plasma TF has been reported in a murine model of HFE-related HH 26 . TFR-1 represents a component of the body iron sensor by directly interacting with HFE in the epithelial cells of the crypts 27 . It is still unproved whether TFR-2, expressed by the basolateral membrane of duodenal crypt cells as TFR-1, interacts with HFE to play a role in iron sensing 25 . Direct binding between HFE and TFR-2 has been ruled out by using soluble forms of these proteins 22 , although in vivo interactions or co-localization have not been conclusively established. As a receptor able to bind TF on the basolateral membrane of the crypt cells, TFR-2 might represent a second sensor of body iron or might participate to a more complex sensing mechanism, as recently hypothesized 28 . The effect of inactivation of TFR-2 by mutations in HH type 3 is in keeping with the loss of a component of the sensing machinery.
The expression of TFR-2 in gut differs from that of DMT1/nramp2, the luminal iron transporter, which localizes prevalently in the enterocytes of the villi and is strongly induced in conditions of iron deficiency in the villus brush border 29, 30 . The distribution of TFR-2 only.
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The finding that the TFR-2 appears to be predominantly cytoplasmic in liver sections is surprising, at least in view of its reported similarity with TFR-1. A possibility is that it is simply due to technical limits in observing the molecule in histological sections:
alternatively, it might reflect the physiological conditions of the liver tissues examined. This In conclusion, we consider the label TFR-2 to be a possible misnomer, the transferrin binding activity being only one aspect of the functions of the molecule. Multi-task molecules are proving not to be an exception, but a rule. Just to cite one related instance, the TFR-1 molecule transports TF and also operates as a receptor for IgA in the kidney 32 . Supporting GAPDH is shown as a control of RNA quality. Representative pictures from 3 different specimens. The TFR-2 protein was stained using G/14C2 mAb.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From and U251 (glioblastoma) were grown on coverslips, exposed to TF for 2 and 6 hrs, respectively, and evaluated for TFR-2 expression. Results show the presence of discrete membrane areas where TFR-2 is localized, more apparent in basal and in 2 hrs conditions. In vitro incubation is paralleled by a constant increase in TFR-2 expression, which appears also uniformly deployed on the surface after 6 hrs incubation. The observed effects are dependent upon the presence of HOLO-TF, APO-TF being ineffective in inducing detectable or comparable effects. The TFR-2 protein was stained using G/14C2 mAb. Representative images from 5 independent experiments. only.
